Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $94
Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $150
Citigroup Raises DexCom Price Target to $91 From $85, Maintains Buy Rating
DexCom Analyst Ratings
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $94
Wells Fargo Remains a Buy on Dexcom (DXCM)
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating, Announces Target Price $90
DexCom Is Maintained at Buy by Canaccord Genuity
DexCom Analyst Ratings
CCORF Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $99
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Sticks to Their Buy Rating for Dexcom (DXCM)
BofA Securities Maintains DexCom(DXCM.US) With Buy Rating
Bank of America Securities Reaffirms Their Buy Rating on Dexcom (DXCM)
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $90
Wells Fargo Sticks to Its Buy Rating for Dexcom (DXCM)
Wells Fargo Remains a Buy on Dexcom (DXCM)